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ABSTRACT
Objective: To perform an external validation of all published prognostic models for first-trimester
prediction of the risk of developing preeclampsia (PE).
Methods: Women <14 weeks of pregnancy were recruited in the Netherlands. All systematically
identified prognostic models for PE that contained predictors commonly available were eligible
for external validation.
Results: 3,736 women were included; 87 (2.3%) developed PE. Calibration was poor due to
overestimation. Discrimination of 9 models for LO-PE ranged from 0.58 to 0.71 and of 9 models
for all PE from 0.55 to 0.75.
Conclusion: Only a few easily applicable prognostic models for all PE showed discrimination
above 0.70, which is considered an acceptable performance.
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Introduction
Preeclampsia (PE) is one of the leading causes of mater-
nal and perinatal mortality and morbidity (1). PE com-
plicates approximately 2–5% of all pregnancies (2) and is
characterized by new onset of hypertension and protei-
nuria after 20 weeks of pregnancy (3). Preventive mea-
sures, like prescription of calcium and low-dose aspirin,
started during the first trimester, have been proven to
prevent PE (4,5). Currently, the administration of those
preventive measures is based on the presence of risk
factors known for PE, such as history of PE or chronic
hypertension (6,7). However, combining risk factors in
prognostic models often allows for better risk assessment
compared to single risk predictors.
To date, numerous multivariable prognostic models
have been developed to predict PE (8–10). Recent quality
assessments of first trimester prognostic models for PE
have shown that methodological flaws are frequently pre-
sent (9,10). These flaws, such as low number of events and
inferior selection methods of risk predictors, may limit
the validity and reproducibility of prognostic models.
Moreover, when used in routine antenatal care, their
performance may be worse compared to the development
setting. This emphasizes the importance of external vali-
dation of prognostic models in independent datasets to
assess their clinical value. Up until now, only a few prog-
nostic models for PE have been externally validated (10).
In order to acquire a fair comparison of their predictive
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accuracy, the aim of our study was to perform an external
validation by examining the performance of published
first trimester prognostic models for PE in one indepen-
dent cohort. Models consisting of commonly available
predictors were selected in order to validate models that
are easily applicable in clinical practice with only limited
costs, even in low resource countries.
Methods
Study population
From December 2012 through January 2014 pregnant
women were recruited in the RESPECT cohort (Risk
Estimation for PrEgnancy Complications to provide
Tailored care). A detailed description of the design and
participants of this study has been described previously
(11). In short, all consecutive women were included at
their initial prenatal visit (<14 weeks of pregnancy) in 31
independent midwifery practices (primary care) and six
hospitals (secondary/tertiary care) in the central region
of the Netherlands. During the course of their pregnancy
participants received routine antenatal care according to
Dutch clinical guidelines. In the Netherlands, pregnant
women were considered at high risk of developing PE
when they had a history of PE, a history of intrauterine
growth restriction (requiring childbirth prior to 34
weeks of pregnancy), or a history of a chronic condition
leading to placental insufficiency (e.g. severe renal dys-
function or systematic lupus erythematosus). Only these
women were eligible for administration of aspirin,
resulting in 1 woman using aspirin during pregnancy.
Data on women who miscarried before 16 weeks were
excluded from the analysis.
This study was approved by the medical ethics com-
mittee of the University Medical Center Utrecht (pro-
tocol number 12–432/C) and written informed consent
was obtained from all participants. Results have been
reported conform to the TRIPOD statement (12).
Predictor assessment
At the initial study visit in the first trimester of pregnancy,
several predictors were measured, such as maternal age,
body mass index, and blood pressure. Between 9 and 14
weeks of gestation blood was withdrawn to measure the
biochemical serummarkers pregnancy-associated plasma
protein-A (PAPP-A) and placental growth factor (PlGF).
Maternal characteristics and medical and obstetrical his-
tory were obtained through a self-administered question-
naire in the first trimester of pregnancy. A full description
of all predictor and marker definitions can be found in
Appendix A. Distribution of predictors among original
studies was not reported, because this information was
often lacking.
Outcome assessment
PE was defined according to definition of the
International Society for the Study of Hypertension in
Pregnancy (3). PE was diagnosed if the diastolic blood
pressure was 90 mmHg or higher on at least two
separate occasions after 20 weeks of gestation in pre-
viously normotensive women combined with the pre-
sence of proteinuria of 300 mg or more during 24 h. All
cases of PE as “all PE”. PE cases requiring childbirth
after 34 weeks of gestation were defined as “late-onset
PE” (LO-PE). Cases requiring childbirth before 34
weeks of gestation were defined as “early onset PE”
(EO-PE).
Selection of prognostic models for external
validation
For the selection of prognostic models, we have
updated a systematic review on models for several
obstetric complications previously published by
Kleinrouweler et al. (8). Medline and Embase were
searched from 1 January 2012 till 23 December 2014.
A combination of terms for first trimester of preg-
nancy, PE and a validated search strategy for prediction
modelling studies was used. The exact search details
and a short summary of this systematic review are
provided in Appendix B. We chose to limit our search
to models that consist of commonly available predic-
tors, which are therefore widely applicable in clinical
practice with only limited costs, even in low resource
countries.
Prognostic models predicting PE (all PE or LO-PE)
based on easily measurable predictors, available before
14 weeks of pregnancy, were eligible. Models including
the commonly used biomarkers PAPP-A and PlGF
were also eligible.
For the purpose of external validation, the exact defi-
nition of the predictors included in the model, how the
predictors were measured, and the exact prediction
equation were retrieved from the original publications.
If information on predictor definition, intercepts or
coefficients were missing, authors were contacted by
email (n = 13). Two authors responded and provided
this information. Due to the low incidence of EO-PE in
the RESPECT cohort we had to exclude prognostic
models for EO-PE. Eventually, 18 prognostic models
for all PE or LO-PE remained for external validation in
the current study (13–29). A description of the exact
predictors and equations used for external validation is
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reported in Appendix A and Appendix C, respectively.
Distributions of predictors in the original studies were
not reported as this information was often lacking in the
original publications.
Statistical analysis
Missing values on predictors or outcome in the valida-
tion cohort were imputed by multiple imputation, based
on the assumption that this data was not missing com-
pletely at random, as can directly be concluded from
Table 1 (30). Continuous variables were compared using
t-tests or Mann–Whitney U tests depending on their
distributions, while categorical variables were compared
using X2 test. All possible predictors and outcomes were
used in the imputation model and ten imputations were
performed. Results shown are the results after multiple
imputations, unless otherwise specified. All analyses
were carried out on each of the multiple imputed data-
sets and Rubin’s rules were used to combine the results
into summary estimates (31). Analyses were performed
using the mice and rms packages of R-3.1 for windows
(http://cran.r-project.org).
First, the predicted probabilities for each participant in
the RESPECT cohort were calculated-based on the exact
prognostic models as published, the “original” results.
This can only be performed when the full prediction
rule, including its intercept, is available (Appendix C).
Second, “logistic calibration” was performed to allow
for a fair comparison of the models. For this adjustment,
the linear predictor is used as the only covariate and
a updated calibration slope and intercept were calculated
(32,33). Results are shown as “recalibrated”.
Third, to assess whether the results were not merely the
result of a poor fit on our population, the prognostic
models were completely “refitted” to our population. This
way we were able to quantify each model’s maximal pre-
dictive accuracy which we could compare to the results
after validation of the originally published models (34).
This results in a new intercept and new regression coeffi-
cients for each prognostic model. Results are shown as
“refitted”.
The performance of each prognostic model for PE was
assessed in terms of calibration and discrimination.
Calibration of “original” and “recalibrated” models was
observed using calibration plots. A calibration plot com-
pares the predicted probabilities of PE for each individual
with the observed outcome. The predicted probabilities
equal the observed proportions for all groups, normally
10, when a model is well calibrated. A calibration plot has
an intercept of 0 and a slope of 1 and all groups ideally fit
close to this diagonal line. The updated calibration inter-
cept and slope of the linear prediction after recalibration
were used to assess model estimation and overfitting.
Overestimation is probably present when the calibration
intercept is less than 0, whereas underestimation is prob-
ably present when the calibration intercept is greater than
0. Overfitting of the original prognosticmodel is indicated
by a calibration slope of less 1 (35).
Discrimination was assessed using the area under the
receiver operating characteristic curve (AUC) (36). The
AUC is used to verify whether participants with a higher
predicted risk for PE are indeedmore likely to develop PE.
An AUC of 0.50 offers no statistical improvement over
a random guess, whereas an AUC of 1.00 would mean
perfect prediction for all participants.
Since a history of PE is an important predictor in
most prognostic models, a subgroup analysis was per-
formed in nulliparous women. Discrimination and cali-
bration were re-assessed in this subgroup.
Finally, a table was constructed with the distribution of
women with and without PE among several predicted risk
categories, based on the prognostic models that showed
good calibration (slope > 0.80). The current NICE
(National Institute for Health and Care Excellence) guide-
line for risk reduction of PE was applied to our cohort for
comparison of performance with the prognostic models
(7). This guideline advises to prescribe aspirin in case
women have one or more high-risk factors or two or
more moderate-risk factors.
Results
RESPECT cohort
Our validation cohort included 3,736 pregnant women
of whom 1,662 (44%) were nulliparous. Other baseline
characteristics of our study population are shown in
Table 1. A total of 87 (2.3%) women developed PE of
whom 71 (1.9%) had LO-PE and 16 (0.4%) EO-PE.
Superimprosed preeclampsia occurred in 2 women,
both had LO-PE. In the nulliparous subgroup 65
(4.0%) women developed PE of whom 51 (3.1%) had
LO-PE and 14 (0.9%) EO-PE.
Calibration and discrimination
Table 2 summarizes all predictors that were included in
the prognostic models and measured in our validation
cohort. Original models for all and LO-PE were applied to
the validation cohort when the original publications pro-
vided the full prediction rule, which was the case for 7 out
of 9 all PE models and for 6 out of 9 LO-PE models.
Calibration of prognostic models for all PE and LO-PE
was poor. Most original models for all PE, as well as LO-
PE, seemed to overestimate the risk of PE, as can be seen
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by the predicted risks which were higher than the
observed risks (Figure 1). Recalibration yielded some
improvement, but except for one model risk overestima-
tion (intercept less than 0) was still present (Figure 2). The
models by Baschat et al. 2014, Syngelaki et al. 2011 and
Poon et al. 2008 showed the least overfitting (calibration
slopes above 0.80) for all PE. For LO-PE, Akokelar et al.
2011 and Kuc et al. 2014 both had a calibration slope
above 0.80.
In terms of discrimination, the AUC ranged from 0.55
to 0.72 for all PE (after recalibration) (Table 3). The
models by Plasencia et al. 2007, Poon et al. 2008 and
Syngelaki et al. 2011 had the highest AUC, all above
0.70. When the models were completely refitted to the
study population, the AUC showed only marginal
improvement indicating that the discrimination of the
original models could not be improved by complete refit-
ting on our data set (Appendix D, figure A).
Models that included the history of PE had a higher
AUC than those that did not (Appendix D, figure C). For
LO-PE models the AUC tended to be lower and ranged
from 0.58 to 0.71 (Appendix D, figure A). The models by
Akolekar et al. 2011, Poon et al. 2009 and Poon et al. 2010
all had an AUC of 0.70 or higher. Refitted models again
showed a slight improvement of the AUC. Applying the
prognostic models for all and late-onset PE to a subgroup
of nulliparous women yielded poor discrimination (0.50 to
0.63 and 0.48 to 0.59, respectively) (Appendix D, figure B).
Predicted risk categories
Table 4 shows the number of women who did and did
not develop PE, stratified by predicted risk category for
the refitted prognostic models that were properly cali-
brated for all PE (three models) and LO-PE (two mod-
els). For all PE models, most women who developed PE
were in the highest categories and only few of these
women were in the lowest risk category. For example,
a predicted risk threshold of ≥5% would correctly classify
40% of women who developed PE as high-risk (sensitiv-
ity) and 90% of women who did not develop PE as low-
Figure 1. Calibration plots of original prognostic models.
In case of perfect calibration all groups of predicted probabilities fit close to the diagonal line, corresponding with an intercept of 0 and
a slope of 1 for the calibration plot. Vertical lines in grouped observed represent 95% confidence intervals.
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risk (specificity) for the model of Baschat et al. 2014. For
LO-PE similar results were observed.
In comparison, applying the current NICE guideline
for risk reduction of PE in our cohort would classify
10% of all women at risk for PE with a sensitivity of
28% and specificity of 90% (7).
Discussion
Main findings
In this study, a comparison of nine first trimester prog-
nostic models for all PE and nine prognostic models for
LO-PE showed discrimination between 0.55 and 0.75 and
moderate calibration with slopes of 0.13 to 1.19. Three
models for all PE (Plasencia et al. 2007, Poon et al. 2008
and Syngelaki et al. 2011) and three models for LO-PE
(Akolekar et al. 2011, Poon et al. 2009 and Poon et al.
2010) had an AUC above 0.70 which was not much
improved after completely refitting the models. The
most common predictors in these models were body
mass index (BMI), parity, history of PE, history of chronic
hypertension and ethnicity. Performance in a subgroup of
nulliparous women yielded discrimination below 0.65 for
all models, probably because the history of PE is a strong
predictor in most models. Overall, with a predicted risk
cut-off of ≥5% approximately 40% of all women who will
develop PE can be identified.
Strengths and limitations
Our external validation study is one of the first studies
that compares a large number of published first trime-
ster prognostic models for PE in one single
independent cohort. This prospective multicenter
cohort consisted of both high- and low-risk women,
strengthening the generalizability of our results.
However, some limitations need to be considered.
We restricted this external validation to published
prognostic models that included maternal characteris-
tics and/or two commonly used serum biomarkers
(PAPP-A and PlGF). Thereby, promising prognostic
models for PE including other biochemical markers
and/or uterine artery Doppler assessment might have
been missed. As it appeared especially hard to predict
PE in nulliparous women, a specialized prognostic
approach (combination of maternal characteristics, pla-
cental markers, and vascular markers) would be more
in line with the multifaceted origin of this major preg-
nancy-syndrome and might improve discrimination of
prognostic models for PE in nulliparous women. Also,
we focused on all and LO-PE, but an external validation
of published models for the prediction of EO-PE is
recommended. However, due to its low incidence, this
can probably best be performed by combining datasets
in an individual patient data meta-analysis. Another
advantage of such a study is that it would probably
result in a more ethnically diverse cohort.
Interpretation
Risk factors that are most strongly associated with PE
were often used in prognostic models for PE, e.g. his-
tory of PE and BMI (37). Al-Rubaie et al. provided an
overview of the performance of “simple” risk models
for PE as reported in the original publications and
showed a wide variety of the discriminative ability of
these models (10). More recently, the ASPRE trial
Figure 2. Calibration plots of recalibrated prognostic models.
In case of perfect calibration all groups of predicted probabilities fit close to the diagonal line, corresponding with an intercept of 0 and
a slope of 1 for the calibration plot. Vertical lines in grouped observed represent 95% confidence intervals.
84 M. LAMAIN-DE RUITER ET AL.
showed a detection rate of 38.3% for term PE (38). Our
external validation study confirmed these findings,
especially the poor performance of prognostic models
for LO-PE (detection rate 36%, Table 4).
Some prognostic models that were validated in our
study have been externally validated before. For exam-
ple, the LO-PE model by Scazzochio et al. with an
original AUC of 0.71 showed an AUC of 0.69 in
a previous validation study and was 0.67 in our valida-
tion study (39). For the model for LO-PE by Plasencia
et al. larger differences were observed. Their original
development study showed an AUC of 0.80, where
validation studies showed a significantly lower AUC:
0.72, 0.65 and 0.58 in our validation study (40,41).
Since the calibration slope for the model by Plascensia
et al. was low, the large variation in AUCs may very
well be the effect of model overfitting.
Themain benefit of first-trimester prognosticmodels for
PE is that they help to guide individualized planning of
antenatal care, and to decide on the prescription of pre-
ventive measures such as low-dose aspirin and calcium
supplementation. However, before implementing prognos-
tic models, it is important to assess their true value in an
external validation study. As only a few models showed
proper calibration and discriminationwas limited to 0.76 at
most, the applicability for clinical practice, especially for the
nulliparous subgroup, may be limited. On the other hand,
the discriminative ability of the prognostic models with the
highest AUC outperform current single risk factor strate-
gies. For example, the model by Baschat et al. 2014 can
Table 3. Discriminative ability of all prognostic models in the external validation.
Prognostic model
AUC
Development
AUC
Recalibrated
AUC
Refitted
AUC
Nulliparous
Recalibrated
AUC
Nulliparous
Refitted
ALL PE
Baschat ‘14 0.82
[0.78 to 0.86]
0.68
[0.61 to 0.74]
0.76
[0.71 to 0.81]
0.63
[0.55 to 0.71]
0.64
[0.56 to 0.72]
Giguere ‘14 0.75
[0.69 to 0.81]
0.63
[0.57 to 0.69]
0.64
[0.58 to 0.71]
0.61
[0.54 to 0.69]
0.63
[0.55 to 0.71]
Goetzinger ‘10 0.70
[0.65 to 0.72]
0.55
[0.48 to 0.61]
0.55
[0.49 to 0.61]
0.50
[0.43 to 0.57]
0.50
[0.43 to 0.57]
Goetzinger ‘13 0.76
[0.69 to 0.83]
0.56
[0.50 to 0.61]
0.56
[0.50 to 0.61]
0.52
[0.46 to 0.57]
0.52
[0.46 to 0.57]
Myatt ‘12 0.65
[0.61 to 0.69]
0.64
[0.58 to 0.70]
0.64
[0.58 to 0.70]
0.61
[0.53 to 0.68]
0.62
[0.54 to 0.69]
Odibo ‘11 0.77
[0.63 to 0.81]
0.56
[0.49 to 0.62]
0.57
[0.50 to 0.63]
0.52
[0.45 to 0.59]
0.53
[0.46 to 0.61]
Plasencia ‘07 0.81
[0.80 to 0.82]
0.72
[0.67 to 0.77]
0.73
[0.68 to 0.78]
0.53
[0.45 to 0.59]
0.54
[0.47 to 0.62]
Poon ‘08 0.85
[NR]
0.71
[0.66 to 0.76]
0.76
[0.71 to 0.81]
0.51
[0.43 to 0.59]
0.63
[0.55 to 0.71]
Syngelaki ‘11 NR 0.72
[0.67 to 0.78]
0.75
[0.70 to 0.80]
0.55
[0.47 to 0.63]
0.59
[0.51 to 0.67]
LATE ONSET PE
Akolekar ‘11 NR 0.71
[0.65 to 0.77]
0.72
[0.66 to .78]
0.53
[0.45 to 0.62]
0.54
[0.45 to 0.62]
Crovetto ’14a 0.72
[0.69 to 0.76]
0.66
[0.59 to 0.72]
0.73
[0.67 to 0.79]
0.48
[0.40 to 0.57]
0.57
[0.48 to 0.66]
Crovetto ’14b 0.75
[0.67 to 0.82]
0.58
[0.51 to 0.65]
0.58
[0.50 to 0.65]
0.53
[0.45 to 0.62]
0.53
[0.45 to 0.62]
Kuc ‘13 NR 0.66
[0.60 to 0.73]
0.68
[0.62 to 0.74]
0.53
[0.45 to 0.61]
0.53
[0.45 to 0.61]
Kuc ‘14 0.79
NR
0.67
[0.61 to 0.74]
0.68
[0.62 to 0.74]
0.59
[0.51 to 0.68]
0.60
[0.52 to 0.68]
Plasencia ‘07 0.80
[0.79 to 0.81]
0.58
[0.51 to 0.65]
0.60
[0.53 to 0.67]
0.53
[0.45 to 0.61]
0.55
[0.47 to 0.63]
Poon ’09 0.79
[0.78 to 0.80]
0.70
[0.64 to 0.76]
0.73
[0.67 to 0.79]
0.52
[0.43 to 0.60]
0.57
[0.49 to 0.66]
Poon ‘10 0.80
[0.76 to 0.83]
0.70
[0.64 to 0.77]
0.73
[0.67 to 0.79]
0.53
[0.45 to 0.61]
0.55
[0.47 to 0.63]
Scazzochio ‘13 0.71
[0.66 to 0.76]
0.67
[0.61 to 0.73]
0.69
[0.62 to 0.75]
0.54
[0.45 to 0.62]
0.57
[0.48 to 0.66]
The AUC “development” shows the AUC as reported in the original publication if available. The AUC “recalibrated” shows the AUC per model,
recalibrated to the RESPECT cohort. The AUC “refitted” shows the AUC per model after complete refitting of the prognostic model to the
RESPECT cohort. The AUC “Nulliparous” shows the AUC per model when applied to a subgroup of only nulliparous.
Abbreviations: AUC, area under the receiver operating characteristic curve; PE, preeclampsia; NR, not reported.
Data are presented in mean [95% confidence interval].
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correctly identify 40% of all women who will develop PE at
a predicted risk cut-off point of 5% [Table 4].Moreover, the
findings of the ASPRE trial shows that the incidence of EO-
PE ismore than halved when low-dose aspirin is prescribed
to women who are detected to be at high risk of developing
PE by a prognostic model (42). Therefore, an cost-
effectiveness analysis on the use of prognostic models for
PE to guide the decision-making of preventive measures
would be the next step to provide more insight into the
harms and benefits compared to current single risk factor
strategies.
Although there might be room for improvement of
current prognostic models for all PE, when clinicians
want to make use of a model, we recommend choosing
one of the models for all PE with the highest AUC.
Based on their performance in our external validation,
development or use of first-trimester models predict-
ing LO-PE using only commonly available predictors
is not recommended, especially not for nulliparous
women.
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Table 4. Pregnancy outcome per predicted risk category.
All PE Baschat 2014 Poon 2008 Syngelaki 2011
Predicted risk % no PE % FPR PE % DR no PE % FPR PE % DR no PE % FPR PE % DR
>5.0 369 10 10 35 40 40 309 8 8 21 24 24 398 11 11 33 38 38
4.5 to < 5.0 135 4 14 3 4 44 115 3 12 6 6 31 119 3 14 6 7 45
4.0 to < 4.5 195 5 19 10 11 55 214 6 17 7 8 39 173 5 19 5 6 50
3.5 to < 4.0 244 7 26 5 6 61 397 11 28 17 19 58 211 6 25 6 7 57
3.0 to < 3.5 264 7 33 7 8 69 509 14 42 20 23 82 256 7 32 10 12 69
2.5 to < 3.0 230 6 39 8 10 79 128 4 46 3 4 85 251 7 39 8 9 79
2.0 to < 2.5 188 5 45 6 6 85 5 0 46 0 0 85 201 5 44 5 5 84
1.5 to < 2.0 96 3 47 0 0 85 6 0 46 1 1 86 104 3 47 2 3 86
1.0 to < 1.5 170 5 52 2 2 88 75 2 48 0 0 86 186 5 52 1 2 88
0.5 to < 1.0 1105 30 82 9 10 98 1669 46 94 12 13 100 1068 29 81 9 10 98
<0.5 653 18 100 2 2 100 222 6 100 0 0 100 682 19 100 2 2 100
Late onset PE Akolekar 2011 Kuc 2014
Predicted risk % no PE % FPR PE % DR no PE % FPR PE % DR
>5.0 349 10 10 25 36 36 108 3 3 5 7 7
4.5 to < 5.0 92 3 12 4 6 41 32 1 4 5 7 14
4.0 to < 4.5 146 4 16 3 5 46 58 2 5 1 2 15
3.5 to < 4.0 217 6 22 6 8 54 66 2 7 4 5 20
3.0 to < 3.5 442 12 34 9 13 67 132 4 11 5 6 27
2.5 to < 3.0 407 11 45 11 15 82 233 6 17 7 10 36
2.0 to < 2.5 37 1 46 1 1 83 400 11 28 14 20 57
1.5 to < 2.0 35 1 47 0 0 83 793 22 50 13 18 74
1.0 to < 1.5 91 2 49 1 2 85 1614 44 94 18 26 100
0.5 to < 1.0 1481 40 90 10 14 99 231 6 100 0 0 100
<0.5 371 10 100 1 1 100 0 0 100 0 0 100
PE, preeclampsia; FPR, false positive rate; DR, detection rate
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